1. Characterization of MK-4166, a clinical agonistic mAb that targets human GITR and inhibits the generation and activity of Tregs. (December 2016) Authors: Sukumar, S.; Wison, D.; Yu, Y.; Wong, J.; Naravula, S.; Ermakov, G.; Bhagwat, B.; Grein, J.; Churakova, T.; Mangadu, R.; Sriram, V.; Bailey, W.; Herzyk, D.; Mcclanahan, T.; Willingham, A.; Beebe, A.; Sadekova, S. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S104 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗